Pretty much the rapidity. In the bloodstream, insulin exists in a state of equilibrium:
insulin receptor/monomer <=> monomer <=> dimer <=> multimer <=> hexamer
Beta cells store insulin as the hexamer, and they release it into the blood as the hexamer which then dissociates according to that equation. The monomer is the only active form, however. The insulin receptor binds the monomer very tightly. Once bound the receptor/monomer complex triggers a cascade of events leading to facilitated diffusion of glucose into the cell. The receptor/monomer is then internalized, the complex breaks apart, the insulin is degraded, and the recptor recycled to the surface. Afrezza insulin is just human insulin, and once absorbed follows the same rules.
Insulin degrading enzyme (IDE) is responsible for clearing insulin that is not used. It degrades all four forms of insulin and immediately begins degrading all four in the bloodstream. In effect ā note that this is oversimplifying ā three quarters of the inhaled insulin is basically unused and removed. This is why you have such rapid elimination of afrezza insulin from the system. Two processes are at work simultaneously. As the monomer is being both used and degraded, the equation is constantly re-equilibrating. So, on one hand, you have the receptors binding and pulling monomers out to the left, while, on the other hand, IDE is degrading all four forms with re-equilibration accordingly pulling monomers out to the right.
Lispro is a modified monomer that resists forming polymers. Once it is injected, it is not exposed to IDE in the subcutaneous tissue. It simply diffuses down its concentration gradient into the bloodstream where it either binds a receptor or is degraded. Very little is converted to more complex forms. This why you have the 4U afrezza cartridge as roughly equivalent to 1U of lispro ā 3 of the afrezza insulin are simply metabolized away. It is less rapidly removed since it doesnāt have that right side of the equation destroying 3 inactive insulin and pulling monomers toward it.
A consequence of the rapid metabolism of afrezza insulin is that its concentration rapidly decreases below effective levels as opposed to lispro. The rapid decrease is good at preventing later hypoglycemia but, at the same time, leaves the diabetic exposed to hyperglycemia from late digesting food.
Another consequence might be noted as well. During the trials, in type 1s, afrezza appeared to require increasing doses over time to maintain adequate glucose control as opposed to lispro. Some afrezza users also have reported requiring more afrezza over the weeks subsequent to starting it. Enzymes such as IDE are susceptible to a phenomena known as āinduction.ā If an enzyme is used frequently ā as would be the case with IDE with the very high concentrations of insulin achieved after dosing afrezza ā cells sometimes are induced to make more of the enzyme. In effect, the cell adapts by cranking up its internal factory to increase output of the enzyme to meet the perceived need. Of course, the more IDE available, the more rapidly insulin is degraded. This is likely what is happening in patients who exhibit a need for increased afrezza dosing. Lispro, of course, is subcutaneous and not exposed to IDE there, so it would not exert the same effect.